PeptideStack
5.2kquestions
20kanswers
220users

Is QYB worth the price difference against Chinese Peptide Company on measured results?

Asked 13 Jul 2026Modified 1 min agoViewed 5.1k times
5

Details up front: QYB · Chinese Peptide Company.

I am trying to choose between two options that are usually discussed as though only one exists.

I am not optimising for price, but I am not indifferent to it either.

Which axes does this decision turn on?

vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
shareeditfollowflag
DB
askedDr_Aoife_Brennan20k2713 Jul 2026

5 Answers

Accepted answer first, then by votes
51

Accepted answer

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Cost per milligram, adjusted honestly

StepValueNote
Vial price, 10 mg nominal£34.00As advertised
Nominal cost per mg£3.4034 ÷ 10
Measured content9.2 mgIndependent content assay
Cost per actual mg£3.7034 ÷ 9.2
Dead-space loss, 20 draws4 %80 µL of a 2 mL fill
Cost per delivered mg£3.853.70 ÷ 0.96
First vial, with £110 assay£14.85Testing dominates a single vial

To be exact about it, sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

One laboratory, one method, one submission. Otherwise it is not a comparison.

shareimprove this answerflag
BD
answered · acceptedb_delacroix43k3822 Jul 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
42

Ratings on this site are ours alone and are deliberately not reconciled with anyone else's.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Name the laboratory and the dates or the comparison cannot be reproduced.

shareimprove this answerflag
DV
answereddead_volume56k4828 Jul 2026
17

The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

More usefully, publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

Use a fixed documentation checklist rather than an impression.

edited 2 Aug 2026 by nine_point_nine — added the citation requested in comments

shareimprove this answerflag
NN
answerednine_point_nine60k14827 Jul 2026
7Adding for future readers: ask for the lot-specific certificate before ordering, not after. – tabular_nums 2 months ago
6Adding a vote because this deserves more of them. – day_seven_trough 5 days ago
add a comment
15

Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

Compare content, not purity. Purity clusters and content does not.

shareimprove this answerflag
WO
answeredw_okoye43k13721 Jul 2026
Worth adding that legal position and enforcement posture are different things. – Dr_Rosalind_Achebe 10 months ago
add a comment
-3

Answering this needs the axis. A supplier that is best on paperwork and a supplier that is best on price are both correct answers to different questions.

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.

The caveat is that a comparison is a snapshot of the lots compared, and lots change.

Price per milligram of measured peptide, not per milligram of label claim.

shareimprove this answerflag
TA
answeredtri_gly_ala24k3816 Jul 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.